CD47 is known to play an important role in CD4 + T cell homeostasis. We recently reported a reduction in mice deficient in the Cd47 gene (Cd47 mice were activated, but clonal expansion contracted within 72 h after immunization. We used TCR crosslinking and mitogen activation in vitro to investigate the underlying mechanism. We found that naïve Cd47 2/2 CD4 + T cells exhibited a premature block in proliferation and survival because of impaired activation of LFA-1, despite effective TCR-induced activation. These results identify CD47 as an important regulator of LFA-1 and VLA-4 integrin-adhesive functions in T cell proliferation, as well as recruitment, and clarify the roles played by CD47 in MOG 35-55 -induced EAE.
Introduction
CD47 is a ubiquitously expressed glycoprotein that interacts "in cis" with multiple integrins and "in trans" with SIRPa and SIRPg and TSP-1 and TSP-2 (reviewed in refs. [1, 2] ). Previous studies have shown that CD47 interactions with SIRPs and TSP-1 play an important role in leukocyte recruitment in models of inflammation and platelet adhesion and activation, in immune cell homeostasis and apoptosis, and as a modulator of CD4 + T cell functions (reviewed in ref. [3] ). CD47 also is a marker of "self" and has been proposed as a cancer therapy target in murine hematopoietic cancer models [4] [5] [6] [7] [8] [9] . Recently, we reported that CD47 is in close physical contact with b2 integrins and that CD47 is required for expression of high-affinity forms of LFA-1 and VLA-4 integrins in human T cells [10] . In addition, murine Cd47 2/2 CD4 + Th1 cells have reduced adhesive interactions with TNF-a-inflamed cremaster muscle microvessels and a 50% reduction of TEM in vitro [11] . Importantly, it is well documented that both LFA-1 and VLA-4 are involved in T cell antigen priming by APCs and homing to lymphoid tissues and to sites of immune reactions and inflammation.
Recruitment and reactivation of self-reactive T effector cells in the CNS are considered central mechanisms in the pathogenesis of MS. EAE is an established murine model for MS [12] . EAE is triggered primarily by autoreactive CD4 + Th subsets [13] . Given the importance of CD47 in immune cell function and in expression of high-affinity forms of VLA-4 and LFA-1 and that the phenotype of Cd47 2/2 animals has not been explored in detail in neurologic autoimmune disease models, we examined whether CD47 regulates antigen-dependent T cell responses in a model of MOG -induced EAE. A previous study by Han and colleagues [14] reported that Cd47 2/2 mice were resistant to active induction of EAE by MOG immunization. They also reported that passive induction of EAE by transfer of in vivo MOG -activated Cd47 2/2 T cells failed to induce disease in WT or recombination-activating gene-deficient mice, whereas transferring WT T cells induced disease in WT and Cd47
2/2
recipients. The authors attributed protection in EAE to complete failure of Cd47 2/2 CD4 + T cell activation. Their conclusion that in vivo MOG -activated Cd47 2/2 T cells transferred to WT recipients did not cause disease is flawed and inconsistent with literature. This is because Cd47 2/2 T cells transferred into WT mice cannot bind SIRPa, expressed by splenic macrophages or DCs to deliver a negative "don't eat me" signal and thus, are rapidly phagocytosed and removed from the circulation, as reported previously [4, 5, 15] . With the use of the same in vivo EAE model, we confirm that Cd47 2/2 mice are completely resistant to MOG -induced EAE, but in contrast to Han and colleagues' study [14] , we demonstrate that CD4 + T cell activation does occur in MOG-immunized Cd47 2/2 animals.
Surprisingly, activated CD4 + T cells failed to sustain proliferation or clonal expansion. Specifically, MOG immunization of Cd47 2/2 mice induced CD4 + T cell activation and T cell entry into cell cycle and cell division, but activated T cells exhibited a striking reduction in clonal expansion within 48 h. We found that defective integrin activation in Cd47 2/2 CD4 + T cells after TCR-XL treatment or mitogen treatments in vitro was responsible for impaired homotypic aggregation, poor proliferation, and subsequent increased apoptosis. Our results indicate that reduced LFA-1 integrin-mediated adhesion and a defect in proliferation of Cd47 2/2 CD4 + T cells upon MOG immunization-not failure in CD4 + T cell activation, as reported previously [14] -are the major mechanisms of protection in MOG -induced EAE.
MATERIALS AND METHODS

Mice
C57BL/6 WT mice from Charles River Laboratories (Wilmington, MA, USA) were used to establish a WT breeding colony in the pathogen-free animal facility at Harvard Medical School, New Research Building (Boston, MA, USA). Generation of Cd47 2/2 mice on the C57BL/6J background has been previously described [16] . Cd47 2/2 mice were obtained from Dr. Eric Brown, while he was a faculty member at University of California (San Francisco, CA, USA) and were used to establish our colony that was used to generate the results (see Figs. 1 and 2 ). Subsequent studies (see Figs. 3-7) were carried out with Cd47 2/2 mice, purchased from The Jackson Laboratory (Bar Harbor, ME, USA), which also were completely protected in the EAE model. Animals from both sources had been backcrossed .10 generations. MOG -specific TCR Tg mice (2D2 mice) were provided by Dr. Vijay Kuchroo (Brigham and Women's Hospital, Boston, MA, USA) [17] . Mice were used at 6-10 wk old for EAE induction or euthanized at 8-12 wk of age for harvest of cells or as otherwise noted.
Study approval
Animal research was performed in accordance with the guidelines of the Committee of Animal Research at the Harvard Medical School and the U.S. purchased from Lonza (Walkersville, MD, USA). Con A and PHA-P were obtained from Sigma-Aldrich (St. Louis, MO, USA). PMA, ionomycin, PI, and FCS were purchased from Sigma-Aldrich. MOG . Murine CXCL12 and CCL21 were from PeproTech (Rocky Hill, NJ, USA). Fluorescent PE-Annexin V apoptosis detection and FITC-BrdU flow kits and the following fluorescent dye-conjugated primary mAb were purchased from BD PharMingen (San Jose, CA, USA): anti-mouse PE-IL-2, allophycocyanin-IL-4, PE-IL-9, allophycocyanin-IL-10, PE-and allophycocyanin-IL-17A, PE-IFN-g, allophycocyanin-forkhead box P3, PE-CD25, FITC-CD62L, PE-Cy7-CD69, PEand allophycocyanin-CD4, FITC-and Pacific Blue-CD8, FITC-and PE-CD11c, allophycocyanin-CD11b, FITC-and allophycocyanin-CD47, PE-Cy7-B220, FITC-and PE-CD44, PE-PD-1, PE-CD28, PE-ICOS, PE-CTLA-4, and PE-CD40L.
Cell isolation
Human CD3 + T cells were isolated to .95% purity by negative selection using RosetteSep negative depletion kits (Stemcell Technologies, Vancouver, BC, Canada) from anti-coagulated whole blood obtained from healthy volunteers [20] . Murine splenic CD11c + DCs and CD4 + T cells were purified by magnetic bead positive separation kits (Miltenyi Biotec, Cambridge, MA, USA). Naïve CD4 + T cells were polarized to Th1 cells by culture with platebound anti-CD3e mAb (5 mg/ml), and RPMI-1640 medium containing anti-CD28 mAb (1 mg/ml), anti-IL-4 mAb (1 mg/ml), and cytokines IL-12 (10 ng/ml) and IL-2 (25 U/ml), as previously detailed [21] . Polarization to Th1 cells was confirmed by measurement of intracellular IFN-g production by flow cytometry.
T cell adhesion to immobilized Fc chimera adhesion molecules under defined laminar shear flow conditions in vitro T cell arrest on immobilized adhesion molecules in a parallel flow chamber has been described previously [21] . In brief, 5 3 10 5 /ml T cells in DPBS with 0.1% BSA and 20 mM HEPES were drawn across immobilized ligands ICAM-1-Fc (10 mg/ml) or VCAM-1-Fc (5 mg/ml) under flow at 37°C. T cell arrest was monitored by video microscopy [10] , and cell adhesion/mm 2 was measured from review of recorded videos.
Induction of EAE and spinal-cord histologic analysis EAE was induced as described [22] . In brief, 6-to 10-wk-old WT and Cd47 TCR-XL using plate-bound anti-CD3e mAb (1 mg/ml) and soluble anti-CD28 mAb (1 mg/ml) or by coculture with mitogens Con A (5 mg/ml) or PHA-P (20 mg/ml) or ionomycin (5 mM) plus PMA (50 ng/ml). Proliferation was monitored by [ 3 H]-thymidine incorporation. Blocking mAb to LFA-1, CD47, ICAM-1, and a combination of 2 different function-blocking anti-VLA-4 mAb were used as purified and azide-free IgG at 20 mg/ml. T cell proliferation was also determined by a flow cytometric assay of CFSE dilution. Purified CD4 + T cells were added to a solution of 5 mM CFSE in PBS at 37°C for 10 min, followed by extensive washing with warm PBS. Cells were cultured as described in text and harvested at different time points after TCR-XL. CFSE fluorescence of gated CD4 + cells was analyzed with FlowJo software to obtain proliferation indices (see Table 2 and Fig. 6 ).
Intracellular cytokine staining and cytokine production assays
For intracellular cytokine staining, cells were activated with 100 ng/ml PMA and 5 mg/ml ionomycin for 4 h in the presence of GolgiStop (BD PharMingen) and stained by anti-cytokine mAb and appropriate isotypematched control antibodies [21] . Cell fluorescence was measured in the CD4 + population by flow cytometry. For analysis of IL-4-, IL-6-, IL-17A-, and IFNg-producing cells, splenocytes (2 3 10
5
) from immunized mice were activated with MOG for 24 h in antibody-coated ELISPOT plates, and spots were counted by an ELISPOT image analyzer (Cellular Technology, Cleveland, OH), as reported previously [22] . Leukocyte subtypes and expression of surface activation markers and costimulatory proteins were measured by appropriate mAb and flow cytometry [21, 22] . Intracellular staining of antiapoptotic Bcl-xL protein was performed exactly as reported [23] . In brief, T cells were harvested, washed in DPBS, fixed in 2% PFA-PBS for 20 min at room temperature, washed twice with PBS, and permeabilized with 0.5% saponin-PBS containing 20% FBS (perm buffer). Cells were incubated with mouse anti-Bcl-xL (1 mg/ml) or no primary mAb in 50 ml perm buffer for 30 min at room temperature, washed twice with perm buffer, and incubated at room temperature for 20 min with goat anti-mouse Alexa 647-labeled secondary mAb in perm buffer. Cells were then washed and analyzed by flow cytometry.
Naïve T cell stimulation by TCR-XL in suspension
Naïve CD4 + T cells (2 3 10 6 cells/ml) in RPMI 1640 + 0.2% FCS were treated with anti-CD3e (2.5 mg/ml) and anti-CD28 (2.5 mg/ml) mAb for 15 min on ice. After washing to remove the first mAb, secondary antibodies (goat antiArmenian hamster and goat anti-mouse; Jackson ImmunoResearch Laboratories, West Grove, PA, USA) were added (2.5 mg/ml) using the same medium and incubated for 15 min on ice. T cells were washed once and resuspended to 2 3 10 6 cells/ml in RPMI 1640 and kept on ice until stimulation was initiated at 37°C. Incubations were halted by addition of formaldehyde (diluted to 4% final concentration) and incubation at 37°C for 15 min. After chilling for 1 min on ice, T cells were centrifuged, resuspended in ice-cold 90% methanol, and incubated on ice for 30 min. Then, cells were stained with primary-labeled phospho-specific mAb for 1 h at room temperature, washed, and resuspended in 1% formaldehyde in PBS for flow cytometry.
T cell-cycle analysis
Naïve T cells were activated by TCR-XL with plate-bound mAb and incubated for different time points, harvested, fixed by drop-wise addition of 100% icecold ethanol, while vortexing to a final concentration of 75% ethanol, and incubated on ice for 1 h. Cells were washed in PBS and incubated in PI solution (50 mg/ml, 100 mg/ml RNase A, and 3.8 mM sodium citrate) for 3 h on ice. Cell-cycle profiles were assessed by flow cytometry and analyzed by FlowJo software.
Analysis of CD4 + T cell apoptosis
Naïve, splenic WT and Cd47 2/2 CD4 + T cells were activated by TCR-XL with plate-bound anti-CD3e (1 mg/ml unless stated otherwise) and addition of 1 mg/ml anti-CD28 mAb to the media, cultured for various times, and harvested to assess cell apoptosis. Annexin V staining and detection of DNA fragmentation using an APO-BrdU TUNEL assay kit (Thermo Fisher Scientific) were performed by following the manufacturer's instructions and analyzed by standard flow cytometry. T cell apoptosis was also assessed by caspase-3 activity in cell lysates by quantification of light emission at 400 nm chromophore p-nitroaniline after cleavage by caspase-3 from the labeled DEVD-p-NA (Kit #ab39401; Abcam, Cambridge, MA, USA).
Statistics
Statistical analyses used Prism 5 software (GraphPad Software, La Jolla, CA, USA). Data are expressed as means 6 SEM. Data were analyzed by unpaired 2-tailed Student's t test between 2 groups and 1-way ANOVA for .2 groups, with P , 0.05 considered significant.
RESULTS
CD47 regulates TCR-XL and chemokine-induced LFA-1-and VLA-4-mediated arrest on ICAM-1 and VCAM-1 in vitro
We previously reported that CD47 is necessary for expression of high-affinity forms of LFA-1 and VLA-4 integrins in CD4 + Th1 cells that bind to their endothelial cell-expressed ligands ICAM-1 and VCAM-1, respectively, after CXCL12 stimulation [10] . To extend our observations, we investigated whether CD47 is necessary for TCR-XL-induced, naïve CD4 + T cell arrest on ICAM-1 and VCAM-1 in an in vitro flow-chamber assay. We found that TCR-XL or coimmobilized CCL21 chemokine increased adhesion of WT but not Cd47 2/2 naïve CD4 + T cells to immobilized ICAM-1 and VCAM-1 (Fig. 1A) Anti-CD47 mAb miap301 reduces LFA-1 and VLA-4 integrin adhesion to ICAM-1 and VCAM-1
Although the amino acid(s) in CD47 that regulate integrin activation have not been identified, we tested whether mAb miap301, which blocks CD47 binding to its in trans ligand SIRPa [24] , interferes with naïve CD4 + T cell adhesion. Pretreatment of WT CD4 + naïve T cells with miap301 mAb reduced TCR-XLinduced adhesion to ICAM-1 and VCAM-1 (Fig. 1B) and also reduced in vitro-generated WT Th1 effector cell adhesion to ICAM-1 coimmobilized with CXCL12 or to VCAM-1 (Fig. 1C) .
Blocking mAb to LFA-1 and VLA-4, but not IgG, blocked T cell adhesion and demonstrated the specificity of this assay. Likewise, purified human CD3 + T cells pretreated with different anti-CD47 mAb that block in trans CD47-SIRPa adhesion (B6H12 and C5D5) also reduced adhesion (Fig. 1D) . In contrast, a nonfunction-blocking anti-CD47 mAb (2D3) had no effect. These data demonstrate that CD47 is necessary for LFA-1 and VLA-4 integrin-dependent adhesion of T cells to their endothelial cell-expressed ligands, ICAM-1 and VCAM-1, respectively. 2C ) revealed abundant mononuclear infiltrates in WT mice but not in Cd47 2/2 animals. These findings corroborate the report by Han and colleagues [14] using this EAE model.
Based on our prior reports that both endothelial cell and T cell CD47 play important roles in T cell recruitment in in vivo and in vitro models [10, 11, 25, 26] , we hypothesized that multiple , as previously reported [21] . Data are means 6 SEM of 3 separate experiments, each done in duplicate coverslips. *P , 0.05; ***P , 0.001 by paired Student's t test. Adhesion of T cells to ICAM-1 + CCL21 (250 ng/ml) was the positive control (n = 2 duplicate coverslips). (B) WT naïve CD4 + T cell adhesion to ICAM-1 and VCAM-1 induced by TCR-XL was reduced by anti-CD47 mAb miap301 mAb (20 mg/ml, 30 min, 37°C). Likewise, blocking LFA-1 and VLA-4 mAb (20 mg/ml) inhibited cell adhesion. Data are means 6 SEM, n = 3 separate experiments performed in duplicate. *P , 0.05; **P , 0.01; ***P , 0.001 compared with WT T cells (black solid bars). (C) Adhesion of in vitro-differentiated WT CD4 + Th1 cells to ICAM-1 + CXCL12 (250 ng/ml) and to VCAM-1 was reduced by blocking CD47 with miap301 mAb and by anti-LFA-1 and VLA-4 mAb. Data are means 6 SEM, n = 3 separate experiments performed in duplicate. *P , 0.05; ***P , 0.001 vs. IgG control (all mAb used at 20 mg/ml). (D) Human peripheral blood CD3 + T cells (.95% purity) were pretreated with mAb to CD47 (B6H12 or C5D5), which blocks CD47 binding to SIRPa [42, 43] or VLA-4 (HP2/1), class I (W6/32), nonblocking anti-CD47 (2D3), or anti-LFA-1 mAb (TS1/22; all mAb are purified IgG, 20 mg/ml) for 30 min. T cell adhesion to human ICAM-1-Fc coimmobilized with CXCL12 or immobilized VCAM-1-Fc or E-selectin-Fc chimeras was measured under shear stress conditions, as we have published [21] . Data are means 6 SEM, performed in duplicate, n = 3-5 separate experiments. *P , 0.05 compared with no addition. defects converge to confer resistance in Cd47 2/2 mice to EAE.
To address whether CD47 expressed in the host is required for susceptibility to EAE, we adoptively transferred in vitro-polarized Thy1. was dramatically impaired compared with WT cells (Fig. 3B ). Cd47 2/2 mice also produced significantly fewer IFN-g-and IL-17A-producing cells compared with WT mice (Fig. 3C and D) , as well as IL-4-and IL-6-producing cells (data not shown), as determined by ELISPOT assay. This general reduction in cytokine profile suggested a defect in proliferation rather than a skewed T cell effector differentiation. To investigate this proliferation defect in vivo, we monitored proliferation specifically in CD4 + T cells by BrdU incorporation and flow cytometric analysis. CD4 + T cells from dLNs of immunized WT mice proliferated by DPI 3, whereas no significant increase over baseline (1.6 6 0.25%) was detected in immunized Cd47 2/2 mice (Fig. 3E) . To distinguish whether lack of priming was a result of a defect in the Cd47 2/2 T cell or DC, we performed a "crisscross" MOG 35-55 -driven in vitro proliferation assay.
Cd47
2/2 CD4 + T cells showed a dramatic defect in proliferation when cultured with WT or Cd47 2/2 CD11c + DCs (Fig. 3F) . WT T cells showed less proliferation when cultured with Cd47 2/2 vs. WT DCs.
Overall, these data demonstrate that Cd47 2/2 CD4 + T cells exhibit a significantly reduced proliferative response to MOG immunization compared with WT, and the defect resides primarily in the CD4 + T cell. Figure 4A shows the gating scheme, and Fig. 4B shows the results. WT and Cd47 2/2 CD4 + T cells produced comparable levels of intracellular IL-17A and IL-4 cytokines, whereas Cd47 2/2 produced greater amounts of IL-9, IL-10, and IFN-g. (Fig. 4C) . Surprisingly, the percent of isolated, naïve CD4 + T cells that expressed surface activation markers CD44 hi , CD69, and CD25 was significantly greater in Cd47 2/2 compared with WT animals (Fig. 4D ). This finding is consistent with CD47 acting as a (Fig. 5A) . Moreover, distal activation markers, including increases in surface-expressed CD44 hi , CD25, CD69, and PD-1; down-regulation of CD62L surface expression; and elevated intracellular IL-2 production were nearly identical in WT and Cd47 2/2 T cells ( Fig. 5B and C) . However, despite the fact that T cell proliferation was 32-48% less than WT T cells (Fig. 5D ). These findings demonstrate that Cd47 2/2 CD4 + T cells do not exhibit a global defect in TCR proximal or distal signal transduction required for IL-2 autocrine production and increased expression of surface markers of activation or intracellular cytokine production.
CD4 + T cells in
Impaired proliferation in Cd47 2/2 T cells upon TCR-XL activation in vitro
To identify the underlying defects in Cd47 2/2 T cell proliferation farther downstream of TCR-XL, we investigated the cell-cycle and cell proliferation. Cd47 2/2 T cells displayed no significant differences from WT in the cell-cycle progression, up to 48 h, as illustrated in Fig. 6A ; however, Cd47 2/2 T cells exhibited a striking reduction in proliferation, as demonstrated by the differences in the kinetics of TCR-XL-induced CFSE dye dilution (Fig. 6B) . The calculated indices using FlowJo software are summarized in (Fig. 6C ). This increase in apoptosis of Cd47 2/2 compared with WT CD4 + T cells was corroborated by increased TUNEL staining of fragmented DNA and by elevated caspase-3 activity (Fig. 6D and E) . The antiapoptotic proteins of the Bcl-2 family are actively regulated in T cells (reviewed in ref. [28] ). As previous studies showed that the Bcl-xL gene was an important survival factor induced in CD4 + T cells by TCR-dependent activation, we examined whether its expression was impaired in Cd47 2/2 T cells [23, [29] [30] [31] . As shown in Fig. 6F , this was not the case, as Bcl-xL protein was elevated, to a similar level, in both cell types by TCR-XL activation. This result suggests other family members, including anti-and proapoptotic, are involved, and their identity requires additional detailed studies.
CD47 and LFA-1 are essential for CD4 + T cell proliferation in vitro
As lack of CD47 impaired the expression of high-affinity LFA-1 and VLA-4 conformations in the human Jurkat CD4 + T cell line [10] , we examined TCR-XL-induced homotypic aggregation of naïve WT and Cd47 2/2 CD4 + T cells after 48 h of in vitro culture.
From the literature, LFA-1 and VLA-4 integrin-dependent homotypic T cell aggregation is an established hallmark of efficient TCR-and mitogen-mediated activation and proliferation in vivo and in vitro [32] [33] [34] [35] [36] . (Fig. 7B) . A more striking observation was the near-complete lack of proliferation by Cd47 2/2 T cells incubated with PHA-P or Con A lectins, which initiate proliferation by capping surface proteins, including the TCR, CD2, signaling lymphocyte activating molecule family (SLAMs), and other costimulatory molecules ( Fig. 7C and D) . We next validated the role of LFA-1 and ICAM-1 in proliferation of WT T cells induced by PHA-P or Con A. Proliferation was totally abolished by anti-LFA-1 to the level of Cd47 2/2 T cells and significantly reduced by ICAM-1 mAb. In contrast, a combination of 2 function-blocking VLA-4 mAb again had no inhibitory effect ( Fig. 7C and D) . Given these results, we next asked if failure of Cd47 2/2 T cells to proliferate was an intrinsic T cell defect by culturing these cells with PMA plus ionomycin, a stimulus that bypasses surface receptors and activates key intracellular pathways of proliferation. PMA plus ionomycin induced robust clustering and proliferation in both WT and Cd47 2/2 CD4 + T cells. This indicates that Cd47
2/2
T cells do not have intrinsic defects in proliferation or cytokine production pathways (Figs. 4 and 5) . As our prior studies revealed that CD47 is in close physical contact with and regulates b2 integrin activation [10] , these results further underscore the critical requirement for CD47 in TCR-XL and mitogen-stimulated T cell clustering and clonal expansion in this model and in vitro proliferation assays. In the final set of experiments, we tested whether targeting CD47 altered T cell proliferation. A rat anti-mouse CD47 mAb (clone miap301) was shown to inhibit completely CD47-dependent thymocyte and erythrocyte binding to immobilized SIRPa, its "trans" ligand [24] . Whereas this mAb reduced T cell arrest on ICAM-1 and VCAM-1 ( Fig. 1) , surprisingly, miap301 mAb did not reduce TCR-XL-, PHA-P-, and Con A-stimulated proliferation (Fig. 7F , filled bars, and G). Thus, this mAb does not reproduce the effect on T cell proliferation observed in Cd47 2/2 CD4 + T cells. Whereas a prior study in human T cells reported that some but not all mAb to CD47 were capable of costimulation with anti-CD3e mAb [37] , we did not detect any effect on proliferation (Fig. 7F , open bars).
DISCUSSION
Our observation that mice lacking CD47 are protected in EAE is consistent with defects in T cell LFA-1 and VLA-4 integrinadhesive functions and emphasizes the importance of CD47 in adaptive immune cell responses in a self-antigen-driven murine disease model. The data herein demonstrate that CD4 + T cells become activated in MOG (Figs. 2 and 3) . We do not exclude, however, the contribution of impaired T cell homing and recruitment of T effectors cells, including regulatory T cells, Th1 or Th17, as well as myeloid cells to the CNS during initiation and/or effector phases of EAE. Future studies are needed to address this possibility. Based on our recent report that CD47 associates b2 integrin in T cells and that CD47 is necessary to induce high-affinity conformations of LFA-1 and VLA-4 integrins required for adhesion and TEM [10] , we initially postulated that defects in VLA-4 and LFA-1 function were responsible for the blockade in proliferation and increased apoptosis. Indeed, integrins are well documented to participate in homotypic aggregation and proliferation of T cells and in resistance to apoptotic stimuli, especially signals that activate the intrinsic (mitochondrial) death pathway (reviewed in ref. [38] ). Our investigation shows both MOG immunization and TCR-XL stimulation in vitro failed to induce proliferation and clonal expansion comparable with their WT counterpart. Whereas our early results revealed that MOG immunization of Cd47 2/2 mice led to an increase in cell numbers in the dLN (Fig. 3A) , further results from in vivo and in vitro experiments showed that Cd47 2/2 CD4 + T cells were not able to cause disease, mostly likely as a result of failure to proliferate ( Fig. 3B-E) or failure to migrate from dLNs to the CNS or both. In fact, activation of Cd47 2/2 CD4 + T cells resulted in elevated apoptosis, which was not related to impaired expression of the anti-apoptotic protein Bcl-xL (Fig. 6 ). There is significant literature for CD47-mediated cell death in a variety leukocytes and other cell types, as reviewed by Oldenborg [3] , and therefore, additional experiments are necessary to identify the molecular mechanisms underlying apoptosis of activated
Cd47
2/2 T cells that we report here. Lastly, our data demonstrate that CD4 + T cell proliferation relies, in part, on LFA-1 activation and binding to ICAM-1, especially in response to mitogens. We infer that MOG -activated Cd47 2/2 T effector cells that do proliferate and survive in immunized Cd47 2/2 mice are likely to have defects in homing to the CNS, and additional studies are required to assess this possibility. These findings highlight the important and multiple roles of Cd47 in T cell activation and the cellular mechanisms that lead to protection of Cd47 2/2 mice in the MOG -induced EAE model. Although our data identify defects in T cell integrins as the dominant mechanism for failure of clonal cell expansion with resulting increased apoptosis, we suggest that defects in integrin functions in DCs and monocytes also contribute to protection in EAE. Prior studies found impaired DC migration to LNs upon antigen immunization in vivo in Cd47 2/2 animals [39, 40] . Other investigators found that anti-CD47 mAb miap301 blocked monocyte transmigration across brain endothelial monolayers in a murine in vitro model [41] . Although the authors of these publications did not identify a role for CD47 regulation of leukocyte integrins, we propose such a defect would have contributed to impaired myeloid cell migration. The latter report also found that blocking mAb to monocyte SIRPa or to endothelial CD47 also attenuated transmigration, further implicating the CD47-SIRPa pathway in monocyte recruitment. A surprising result was that although the anti-CD47 mAb miap301 was found to block CD47 binding to murine SIRPa [24] and reduced Th1 T cell arrest on ICAM-1 and VCAM-1 (Fig. 1D) , the mAb did not block naïve CD4 + T cell proliferation in vitro induced by Con A or PHA-P lectins or TCR-XL, as shown in Fig.  7G . The blocking effect of this mAb on adhesion of murine T cells to ICAM-1 and VCAM-1 was proportional to the level of inhibition of human T cell arrest on ICAM-1 and VCAM-1 by antihuman CD47 mAb (Fig. 1D ) that also blocked CD47 binding to SIRPa [42, 43] . We did not, however, predict the lack of inhibition on T cell proliferation by miap301 mAb, and differences in results between T cells deficient in CD47 and the anti-CD47 antibody treatment remain unexplained. A likely explanation is that mAb miap301 does not fully block CD47 in cis and in trans association with other proteins required in proliferation of T cells and potentially other immune cells. Alternatively, perhaps CD47 performs actions that promote proliferation in the absence of binding ligand. We previously reported that miap301 mAb stained WT T cells, neutrophils, monocytes, and endothelial cells but not these same cell types from Cd47 2/2 animals, indicating specificity for murine CD47 [26] . We speculate that miap301 mAb interferes with in cis CD47-integrin association as a result of steric hindrance, but this clearly requires future study.
Our results with the miap301 mAb provide some insight into the previous report by Han and colleagues [14] that coadministration of MOG with anti-CD47 mAb reduced paralysis, whereas mAb, given at peak of paralysis, worsened disease (a Janus-like, opposing effect). We speculate that worsening paralysis by mAb miap301 infusions is a result of impaired recruitment and/or proliferation of T regulatory cells or other cell types that normally dampen the immune response to MOG [44] [45] [46] [47] [48] .
On the other hand, it is difficult to predict the outcome when using rat anti-mouse blocking mAb to CD47 interactions in vivo as a result of short half-life of a rat mAb in mice and of CD47 multiple in cis and in trans partners in immune and nonimmune (i.e., endothelium and epithelium) cell types. Given the emerging role of antibodies that target CD47 or SIRPa as an immunotherapy in cancer models [49, 50] , a better understanding of the effect of current or newly generated mAb on CD47 binding to SIRPs or impairing leukocyte or endothelial cell integrin functions is important.
Han and colleagues [14] recently reported that Cd47 2/2 mice were protected in the MOG -induced EAE model as a result of complete failure in T cell activation. Our much more in-depth in vivo and in vitro studies do not support this conclusion. It is likely the differences are related to their not appreciating that CD47 is necessary for LFA-1 integrin function in adhesion and antigen-and lectin-dependent proliferation. These authors also did not appreciate prior reports demonstrating that Cd47 2/2 cells injected into WT animals do not survive [5, 15] . Thus, their conclusion that Cd47 2/2 T cells isolated from MOG 35-55 -immunized Cd47 2/2 mice and then transferred into WT did not cause disease is not interpretable. Prior studies supported an important role for CD47 and its ligands SIRPa and TSP-1 in immune-mediated disease and as a potential therapeutic target in such diseases. Knock-in Tg mice expressing a nonsignaling, truncated SIRPa molecule are also protected in MOG -induced EAE as a result of failure of DCs to prime T cells and to proliferate [51] and in a collagen-induced arthritis model [52, 53] . Tsp1 2/2 mice also show milder disease in EAE [54] . We suggest the Janus-like, opposing effect of CD47 does not negate its value as a therapeutic target based on the literature. Notably, initial studies that targeted other therapeutically important immune molecules, including CTLA-4, VLA-4, and CD28, have also reported Janus-like opposing effects before their functions in immune cells were fully understood [55] [56] [57] [58] . We conclude that lack of sustained LFA-1 integrin-dependent proliferation in Cd47 2/2 CD4 + T cells upon MOG immunization is the major mechanism for protection in the MOG -induced EAE model, although we do not discount the potential contribution of impaired T cell homing and/or recruitment of T effector cells (regulatory T cells, Th1, or Th17) or myeloid to the CNS. Boston, MA, USA) and Vicki A. Boussiotis (Beth Israel Deaconess Medical Center, Boston, MA, USA) for helpful discussions on T cell apoptosis.
DISCLOSURES
